Garenoxacin mesylate is a Small Molecule owned by FUJIFILM Toyama Chemical, and is involved in 7 clinical trials, which were completed.
Garenoxacin mesylate is a topoisomerase IV, DNA gyrase inhibitor. It works by inhibiting bacterial DNA gyrase (main target in gram negative bacteria) and topoisomerase IV (main target in gram +ve bacteria). The major mechanism of action requires cell division quinolones also have other mechanisms of action which result in them being active against bacteria that are not actively replicating. The cross outer membrane of gram negative bacteria via porins affinity for bacterial target enzymes is 1000 times that for equivalent human enzymes minimum inhibitory concentration (MIC) is increased in the presence of magnesium and in acid environments (pH <6). It acts by inhibition of a metabolic pathway and disruption of bacterial membrane structure.
The revenue for Garenoxacin mesylate is expected to reach a total of $99m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Garenoxacin mesylate NPV Report.
Garenoxacin mesylate is originated and owned by FUJIFILM Toyama Chemical. Astellas Pharma and Taisho Pharmaceutical Holdings are the other companies associated in development or marketing of Garenoxacin mesylate.
Garenoxacin mesylate Overview
Garenoxacin mesylate (Geninax) is a quinolone derivative, acts as antibiotic or antibacterial agent. It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of infections such as pharngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, chronic respiratory lesions secondary infection, otitis media and sinusitis caused by susceptible microrganisms.
Garenoxacin mesylate (Geninax, T-3811) was under development for the treatment of bacterial infections in Japan as injectable formulation, and in EU and US as oral and injectable formulations.
Astellas Pharma Overview
Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,296,163 million for the fiscal year ended March 2022 (FY2022), an increase of 3.7% over FY2021. In FY2022, the company’s operating margin was 12.4%, compared to an operating margin of 11.7% in FY2021. In FY2022, the company recorded a net margin of 9.6%, compared to a net margin of 9.7% in FY2021. The company reported revenues of JPY380,394 million for the second quarter ended September 2022, a decrease of 0.4% over the previous quarter.
Quick View – Garenoxacin mesylate
|Highest Development Stage|